FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to a self-emulsifying composition of a drug based on a flavonoid polyphenol for obtaining drugs for the treatment of diseases, a method for producing the above composition, a pharmaceutical composition for obtaining drugs for the treatment of diseases, containing the above self-emulsifying composition, and the use of the above the self-emulsifying composition or the above pharmaceutical composition for the preparation of medicaments for the treatment of diseases. Self-emulsifying composition of a medicinal product based on a flavonoid polyphenol for the preparation of drugs for the treatment of diseases selected from the group: against bacteria, against viruses, anti-inflammatory agents, agents for suppressing allergies, agents for regulating immunity, antitumor agents, antioxidants, anti-aging agents, agents against anti-ultraviolet radiation, hormone deficiency agents, anti-hypertension agents, blood fat-lowering agents, atherosclerosis agents, senile dementia agents, enterovirus vesicular stomatitis agents, osteoporosis agents or liver protection agents, containing a drug complex a flavonoid polyphenol-based phospholipid, an oil phase, an emulsifier and a co-emulsifier, wherein the flavonoid polyphenol-based drug is baicalein; the mass ratio of baicalein and phospholipid is 1:1-1:8; the oil phase is one or more selected from the group consisting of ethyl oleate, isopropyl myristate and caprylic/capric acid glyceride; the emulsifier is one or more selected from the group consisting of caprylic/capric acid polyethylene glycol glyceride, Tween 80, octylphenyl polyoxyethylene ether; the co-emulsifier is propylene glycol monocaprylate and/or diethylene glycol monoethyl ether; and in terms of the total mass fraction of the oil phase, emulsifier and co-emulsifier, which is 100%, the oil phase is 10–30%, the emulsifier is 40–60% and the co-emulsifier is 30–40%. A method for producing the above self-emulsifying drug composition based on a flavonoid polyphenol, comprising the following production steps: (1) preparation of a flavonoid polyphenol-phospholipid drug complex: a flavonoid polyphenol-based drug and a phospholipid are dissolved in an organic solvent, coupled, and dried to remove the organic solvent to obtain a flavonoid polyphenol-phospholipid drug complex; (2) preparation of a self-emulsifying flavonoid polyphenol drug composition: the flavonoid polyphenol-phospholipid drug complex obtained in step (1) is fully mixed with the oil phase, emulsifier, and co-emulsifier in any order. Pharmaceutical composition for the preparation of medicines for the treatment of diseases selected from the following group: against bacteria, against viruses, anti-inflammatory agents, agents for suppressing allergies, agents for regulating immunity, antitumor agents, antioxidants, anti-aging agents, agents against ultraviolet radiation, agents for the treatment of deficiency hormones, anti-hypertension agents, blood fat-lowering agents, anti-atherosclerosis agents, anti-senile dementia agents, enteroviral vesicular stomatitis agents, osteoporosis agents or liver protection agents, containing the above self-emulsifying flavonoid polyphenol-based drug composition and a pharmaceutically acceptable excipient. Use of the above self-emulsifying flavonoid polyphenol-based drug composition or the above pharmaceutical composition for the preparation of medicines for the treatment of diseases selected from the group of anti-bacteria, anti-virus, anti-inflammatory agents, allergy suppressants, immune-regulatory agents, antitumor agents, antioxidants , anti-aging agents, anti-ultraviolet agents, agents for the treatment of hormone deficiency, agents for hypertension, agents for lowering blood fats, agents for atherosclerosis, agents for senile dementia, agents for the treatment of enteroviral vesicular stomatitis, agents for osteoporosis, or agents for protection liver.
EFFECT: above group of inventions makes it possible to increase the drug load of the composition, to increase the stability and bioavailability of the compositions.
17 cl, 2 dwg, 13 tbl, 16 ex
